The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE had asked Supriya Lifescience to clarify why segment details were not included in its financial results for the quarter ended 30 June 2025, under SEBI's Listing Regulations (Regulation 33). The company has now submitted its response to the exchange. This pertains to the standard disclosure requirement of providing segment-wise revenue and performance data as part of quarterly results.
This is a routine exchange query on a reporting compliance matter, not a punitive action. Investors should review the company's response to see if segment disclosures reveal anything material about business mix, but there is no immediate negative implication for shareholders.